

Title (en)

ASSESSMENT OF CANCERS FOR TREATMENT WITH A CD33/CD3 BISPECIFIC T CELL ENGAGER

Title (de)

BEURTEILUNG VON KREBS ZUR BEHANDLUNG MIT EINEM CD33/CD3-BISPEZIFISCHEN T-ZELL-ENGAGER

Title (fr)

ÉVALUATION DE CANCERS POUR LE TRAITEMENT AVEC UN ANTICORPS BITE CD33/CD3

Publication

EP 4240406 A1 20230913 (EN)

Application

EP 21816264 A 20211105

Priority

- US 202063110011 P 20201105
- US 2021058254 W 20211105

Abstract (en)

[origin: WO2022099006A1] Methods for assessing potential for treatment of certain cancers with a bispecific T cell engager having two CD33 binding domains and two CD3 binding domains are described. The methods entail assessing clustering of CD33 on tumor cells, e.g., leukemic blast.

IPC 8 full level

A61K 39/00 (2006.01); **A61P 35/02** (2006.01); **C07K 16/28** (2006.01)

CPC (source: EP)

A61P 35/02 (2017.12); **C07K 16/2803** (2013.01); **C07K 16/2809** (2013.01); **C07K 16/2818** (2013.01); **A61K 2039/505** (2013.01); **A61K 2039/507** (2013.01); **C07K 2317/24** (2013.01); **C07K 2317/31** (2013.01); **C07K 2317/626** (2013.01); **C07K 2317/73** (2013.01); **C07K 2317/75** (2013.01); **C07K 2317/76** (2013.01)

Citation (search report)

See references of WO 2022099006A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

Designated validation state (EPC)

KH MA MD TN

DOCDB simple family (publication)

WO 2022099006 A1 20220512; EP 4240406 A1 20230913

DOCDB simple family (application)

US 2021058254 W 20211105; EP 21816264 A 20211105